Biotech Values

[DewDiligence]

The growth number of HCV patients in the undeveloped world will exceed those that receive treatment over the next 10 years IMO. China, India, and SE Asia will be a particularly strong and profitable HCV drug markets if economic growth projections are maintained and intellectual property rights are respected.

Are you confusing HCV and HBV? The latter is a very big health problem in Asia; however, DAAs active against HCV are not active against HBV, so the HBV epidemic in Asia does not present a business opportunity for HCV drugs other than the interferons.